for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Liminal BioSciences Inc

LMNL.OQ

Latest Trade

4.80USD

Change

-0.15(-3.03%)

Volume

81,449

Today's Range

4.58

 - 

4.86

52 Week Range

3.51

 - 

31.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.95
Open
4.83
Volume
81,449
3M AVG Volume
26.90
Today's High
4.86
Today's Low
4.58
52 Week High
31.45
52 Week Low
3.51
Shares Out (MIL)
29.39
Market Cap (MIL)
145.46
Forward P/E
-1.71
Dividend (Yield %)
--

Next Event

Liminal BioSciences Inc Annual Shareholders Meeting

Latest Developments

More

Liminal Biosciences Provides Update On Business Strategy And Focus On Small Molecule Therapeutics

Liminal Biosciences Receives FDA Approval For Its U.S.-Based Plasma Collection Center

Liminal Biosciences Inc Files Prospectus Related To The Resale By Selling Shareholders Of Up To 14.2 Mln Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Liminal BioSciences Inc

Liminal BioSciences Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for patients suffering from diseases primarily related to fibrosis, including respiratory, liver and kidney diseases. The Company operates through two segments: Small Molecule Therapeutics Segment and Plasma-derived Therapeutics Segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. Its lead small molecule product candidate is fezagepras (PBI-4050). The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Its lead plasma-derived product candidate is Ryplazim (plasminogen).

Industry

Biotechnology & Drugs

Contact Info

440 BOULEVARD ARMAND, FRAPPIER #300

LAVAL, QC

H7V 4B4

Canada

+1.450.7810115

https://prometic.com/

Executive Leadership

Aleksander Krstajic

Non-Executive Chairman of the Board

Kenneth H. Galbraith

Chief Executive Officer, Director

Murielle Lortie

Chief Financial Officer

Bruce Pritchard

Chief Operating Officer - International

Patrick Sartore

Chief Operating Officer - North America

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2020(E)

0.0K
EPS (CAD)

2020(E)

-3.658
Price To Earnings (TTM)
0.25
Price To Sales (TTM)
55.00
Price To Book (MRQ)
4.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
209.63
LT Debt To Equity (MRQ)
189.06
Return on Investment (TTM)
-89.63
Return on Equity (TTM)
-78.09

Latest News

Latest News

BRIEF-Liminal BioSciences Commences Collection Of Convalescent Plasma From COVID-19 Recovered Donors

* LIMINAL BIOSCIENCES COMMENCES COLLECTION OF CONVALESCENT PLASMA FROM COVID-19 RECOVERED DONORS Source text for Eikon: Further company coverage:

BRIEF-Liminal BioSciences Provides Guidance Update On Certain Expected Key Milestones For 2020

* LIMINAL BIOSCIENCES PROVIDES GUIDANCE UPDATE ON CERTAIN EXPECTED KEY MILESTONES FOR 2020

BRIEF-Liminal BioSciences Says Net Loss From Continuing Operations Was $27.7 Million

* LIMINAL BIOSCIENCES INC - DURING Q1, COVID-19 DID NOT HAVE A MATERIAL IMPACT ON UNDERLYING BUSINESS OPERATIONS OR FINANCIAL CONDITION

BRIEF-Liminal Biosciences says To Date, Have Not Had Any Material Disruptions To Ongoing Business Activities From COVID-19

* LIMINAL BIOSCIENCES- TO DATE, HAVE NOT HAD ANY MATERIAL DISRUPTIONS TO ONGOING BUSINESS ACTIVITIES FROM COVID-19

BRIEF-Liminal Biosciences Q4 Loss Per Share $0.62

* LIMINAL BIOSCIENCES REPORTS FOURTH QUARTER AND 2019 YEAR END RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up